Kedudukan dalam Saham
#35289
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
Harga Saham
$0.82959892
Disegerakkan terakhir: 2023-05-23
Perubahan (1 hari)
-0.04%
Perubahan (1 tahun)
0.00%
Perdagangan IMV Inc. (IMV)
Harga IMV dengan permodalan pasaran b
Modal pasaran bagi IMV Inc.(IMV)
Modal Pasaran: $4.16M
Sehingga August 2026, IMV Inc. mempunyai modal pasaran sebanyak $4.16M. Ini menjadikan IMV Inc. syarikat ke-35289th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran IMV Inc. dari 2012 hingga 2026
IMV berbanding dengan 5 teratas yang paling popular stocks
| Harga IMV |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.452T
|
+131,076,102.29%
|
|
|
|
|
$4.490T
|
+107,950,940.04%
|
|
|
|
|
$4.162T
|
+100,074,320.56%
|
|
|
|
|
$3.676T
|
+88,388,142.13%
|
|
|
|
|
$2.833T
|
+68,113,157.05%
|
